Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
36.71
+0.87 (2.43%)
Sep 26, 2025, 4:00 PM EDT - Market closed
Dianthus Therapeutics Employees
Dianthus Therapeutics had 78 employees as of December 31, 2024. The number of employees increased by 25 or 47.17% compared to the previous year.
Employees
78
Change (1Y)
25
Growth (1Y)
47.17%
Revenue / Employee
$62,231
Profits / Employee
-$1,471,205
Market Cap
1.42B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 78 | 25 | 47.17% |
Dec 31, 2023 | 53 | 21 | 65.63% |
Dec 31, 2022 | 32 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
DNTH News
- 16 days ago - Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 18 days ago - Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering - GlobeNewsWire
- 18 days ago - Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference Call - Seeking Alpha
- 19 days ago - Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering - GlobeNewsWire
- 19 days ago - Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile - GlobeNewsWire
- 20 days ago - Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - GlobeNewsWire
- 7 weeks ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - GlobeNewsWire
- 4 months ago - Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference - GlobeNewsWire